Developing a Diverse Next Generation of Leaders in Respiratory Science

培养多元化的下一代呼吸科学领导者

基本信息

项目摘要

PROJECT SUMMARY/ABSTRACT This proposal is for a new training program that capitalizes on our major local strengths in respiratory physiology and pulmonary disease. Over time, the field of physiology and pathophysiology has evolved to solve new problems identified from clinical management of lung airway, interstitial and vascular diseases and to extend the new discoveries from genetic, genomic, cell and molecular studies to define pathogenic mechanisms and develop novel therapeutic interventions for lung diseases. We remain focused on the importance of integrated function and systems biology and thus we use the concepts of physiology as an integrator across respiratory science studied at multiple levels. With the success of our recent T32 and recruitment efforts, our respiratory science has broadened to include strength in genetics, (epi)genomics, molecular and cellular biology. While we view our science as cutting edge, we pride ourselves on the fact that our trainees do not just focus on a single molecule or gene but rather keep in mind the importance of integrated function and translational research. Our MPIs include diverse strengths in Pulmonary, Sleep, Genomics, Critical Care, Physiology and Respiratory Science. The MPIs have mutual respect, complementary expertise, shared vision for scientific progress and a strong commitment to developing a superb next generation of leaders with rich diversity. To improve the quality of mentoring, we also removed less effective mentors while adding more R01-funded preceptors and formalizing the levels of faculty participation based on success in research training, research productivity and current research funding. We have made both Sleep and Pediatrics as major scientific foci, addressing major national shortages in these areas. We utilize individual development plans, overseen by the MPIs, Preceptors and senior advisors, for all of our trainees to empower people with diverse backgrounds. We promote collaboration between MDs and PhDs, ensure that everyone has experience and competency in inter-, trans- and multi-disciplinary research, and ensure all of our trainees have a strong foundation in physiological approaches that provides a clinical context for research problems studied at any level. We promote cohesiveness, team spirit and a unique identity for our trainees via common activities involving all of our trainees and mentors/preceptors such as frequent scholarly meetings, career development sessions and quarterly retreats. We are committed to a training program that includes every phase of academic career development, from ‘cradle to grave’ including developing junior faculty into independent investigators, and even improving the mentoring skills in our senior faculty. We also remain committed to diversifying the next generation of respiratory scientists as demonstrated by our long- term track record and recent recruitments. The lack of a robust pipeline for multidisciplinary researchers who can apply modern integrative approaches to problems in respiratory science is a crisis which has been further amplified by the COVID pandemic, but it is a challenge that we are well-qualified and eager to address.
项目总结/摘要 这个建议是一个新的培训计划,利用我们在呼吸生理学的主要本地优势 和肺部疾病。随着时间的推移,生理学和病理生理学领域已经发展到解决新的 从肺气道、间质性和血管疾病的临床管理中发现的问题, 从遗传、基因组、细胞和分子研究中获得新发现,以确定致病机制, 为肺部疾病开发新的治疗干预措施。我们仍然关注综合的重要性 功能和系统生物学,因此我们使用生理学的概念作为呼吸系统的整合者。 多层次的科学研究。随着我们最近T32和招募工作的成功,我们的呼吸系统 科学范围已扩大到包括遗传学、(外延)基因组学、分子和细胞生物学。虽然我们 我们认为我们的科学是最前沿的,我们为我们的学员不只是专注于一个单一的 分子或基因,而是要记住整合功能和翻译研究的重要性。我们 MPI包括肺部、睡眠、基因组学、重症监护、生理学和呼吸系统等领域的各种优势 科学多边机构相互尊重,专业知识互补,对科学进步有着共同的愿景, 致力于培养具有丰富多样性的优秀下一代领导者。以提高发展质量 在指导方面,我们还删除了效率较低的指导者,同时增加了更多由R 01资助的指导者, 教师参与水平的基础上成功的研究培训,研究生产力和当前 科研经费我们已经把睡眠和儿科作为主要的科学焦点,解决主要的国家问题。 这些领域的短缺。我们利用个人发展计划,由MPI,Preceptors和高级管理人员监督。 顾问,为我们所有的学员赋予不同背景的人。我们促进合作, 医学博士和博士,确保每个人都有跨学科,跨学科和多学科的经验和能力 研究,并确保我们所有的学员都有一个坚实的基础,在生理方法,提供了一个 临床背景下的研究问题研究在任何水平。我们提倡凝聚力,团队精神和独特的 通过涉及所有学员和导师/导师的共同活动, 频繁的学术会议、职业发展会议和季度务虚会。我们致力于培训 该计划包括学术生涯发展的每一个阶段,从“摇篮到坟墓”,包括发展 初级教员转变为独立调查员,甚至提高我们高级教员的指导技能。我们 我们也将继续致力于使下一代呼吸科学家多样化,正如我们长期以来所证明的那样, 长期跟踪记录和最近的招聘。缺乏多学科研究人员的强大管道, 将现代综合方法应用于呼吸科学问题是一个危机, 新冠肺炎疫情加剧了我们的经济增长,但我们有足够的能力应对这一挑战。

项目成果

期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Secondary infections in critically ill patients with COVID-19 receiving steroid therapy.
  • DOI:
    10.1177/00368504231207209
  • 发表时间:
    2023-10
  • 期刊:
  • 影响因子:
    2.1
  • 作者:
    Pearce, Alex K.;Zawaydeh, Qais;Mcguire, W. Cameron;Husain, Abdurrahman;Ayoub, Claudia;Sweeney, Daniel A.;Cotton, Shannon A.;Malhotra, Atul
  • 通讯作者:
    Malhotra, Atul
Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial.
替泽帕肽治疗阻塞性睡眠呼吸暂停:SURMOUNT -OSA 3 期试验的基本原理、设计和样本基线特征。
  • DOI:
    10.1016/j.cct.2024.107516
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    2.2
  • 作者:
    Malhotra,Atul;Bednarik,Josef;Chakladar,Sujatro;Dunn,JuliaP;Weaver,Terri;Grunstein,Ron;Fietze,Ingo;Redline,Susan;Azarbarzin,Ali;Sands,ScottA;Schwab,RichardJ;Bunck,MathijsC
  • 通讯作者:
    Bunck,MathijsC
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Laura Elise Crotty Alexander其他文献

Laura Elise Crotty Alexander的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Laura Elise Crotty Alexander', 18)}}的其他基金

Convergence of Vitamin E, THC, Nicotine, Propylene Glycol and Glycerin Effects on Lung Inflammation When Vaped
维生素 E、THC、尼古丁、丙二醇和甘油的综合作用对电子烟时肺部炎症的影响
  • 批准号:
    10546469
  • 财政年份:
    2022
  • 资助金额:
    $ 38.31万
  • 项目类别:
Convergence of Vitamin E, THC, Nicotine, Propylene Glycol and Glycerin Effects on Lung Inflammation When Vaped
维生素 E、THC、尼古丁、丙二醇和甘油的综合作用对电子烟时肺部炎症的影响
  • 批准号:
    10371746
  • 财政年份:
    2022
  • 资助金额:
    $ 38.31万
  • 项目类别:
Electronic Cigarette Vapor Inhalation Adversely Affects Lung Cellular and Physiologic Function and Alters Systemic Inflammatory Pathways
电子烟蒸气吸入会对肺细胞和生理功能产生不利影响,并改变全身炎症途径
  • 批准号:
    10220439
  • 财政年份:
    2020
  • 资助金额:
    $ 38.31万
  • 项目类别:
Hypoxia inducible factors in pulmonary endothelial cells regulate allergic inflammatory airways disease
肺内皮细胞缺氧诱导因子调节过敏性炎症性气道疾病
  • 批准号:
    10292906
  • 财政年份:
    2019
  • 资助金额:
    $ 38.31万
  • 项目类别:
Hypoxia inducible factors in pulmonary endothelial cells regulate allergic inflammatory airways disease
肺内皮细胞缺氧诱导因子调节过敏性炎症性气道疾病
  • 批准号:
    10515302
  • 财政年份:
    2019
  • 资助金额:
    $ 38.31万
  • 项目类别:
Hypoxia inducible factors in pulmonary endothelial cells regulate allergic inflammatory airways disease
肺内皮细胞缺氧诱导因子调节过敏性炎症性气道疾病
  • 批准号:
    10045518
  • 财政年份:
    2019
  • 资助金额:
    $ 38.31万
  • 项目类别:
Genetic and Pharmacologic Evaluation of the Role of HIF-1a in asthma
HIF-1a 在哮喘中作用的遗传学和药理学评价
  • 批准号:
    8305975
  • 财政年份:
    2011
  • 资助金额:
    $ 38.31万
  • 项目类别:
Genetic and Pharmacologic Evaluation of the Role of HIF-1a in asthma
HIF-1a 在哮喘中作用的遗传学和药理学评价
  • 批准号:
    8698286
  • 财政年份:
    2011
  • 资助金额:
    $ 38.31万
  • 项目类别:
Genetic and Pharmacologic Evaluation of the Role of HIF-1a in asthma
HIF-1a 在哮喘中作用的遗传学和药理学评价
  • 批准号:
    8143209
  • 财政年份:
    2011
  • 资助金额:
    $ 38.31万
  • 项目类别:
Genetic and Pharmacologic Evaluation of the Role of HIF-1a in asthma
HIF-1a 在哮喘中作用的遗传学和药理学评价
  • 批准号:
    8402123
  • 财政年份:
    2011
  • 资助金额:
    $ 38.31万
  • 项目类别:

相似国自然基金

Next Generation Majorana Nanowire Hybrids
  • 批准号:
  • 批准年份:
    2020
  • 资助金额:
    20 万元
  • 项目类别:

相似海外基金

Next generation vaccines for bovine respiratory disease (BRD) complex utilizing virus vaccine vectors to target both bacterial and viral pathogens.
下一代牛呼吸道疾病 (BRD) 疫苗利用病毒疫苗载体来靶向细菌和病毒病原体。
  • 批准号:
    BB/X017532/1
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
    Research Grant
Next Generation Infectious Disease Diagnostics: Microfluidic-Free Gigapixel PCR with Self-Assembled Partitioning
下一代传染病诊断:具有自组装分区的无微流控千兆像素 PCR
  • 批准号:
    10682295
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
A Flexible High-Throughput Immunological Assay to Support Next-Generation Influenza Vaccine Studies
灵活的高通量免疫分析支持下一代流感疫苗研究
  • 批准号:
    10655239
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
Target Insertion Amplification and Sequence (TIAS): A novel targeted sequencing technology that performs rapid target enrichment and next generation sequencing sample preparation simultaneously
靶标插入扩增和测序(TIAS):一种新颖的靶向测序技术,可同时进行快速靶标富集和下一代测序样品制备
  • 批准号:
    10758909
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
Novel Implementation of Microporous Annealed Particle HydroGel for Next-generation Posterior Pharyngeal Wall Augmentation
用于下一代咽后壁增强的微孔退火颗粒水凝胶的新实现
  • 批准号:
    10727361
  • 财政年份:
    2023
  • 资助金额:
    $ 38.31万
  • 项目类别:
Development and performance testing an agnostic next-generation sequencing assay for detection of respiratory RNA viruses from clinical samples
用于从临床样本中检测呼吸道 RNA 病毒的不可知论下一代测序测定的开发和性能测试
  • 批准号:
    476136
  • 财政年份:
    2022
  • 资助金额:
    $ 38.31万
  • 项目类别:
    Studentship Programs
A comprehensive next generation sequencing diagnostic tool for lung infection among hospitalized patients
住院患者肺部感染的综合下一代测序诊断工具
  • 批准号:
    10547598
  • 财政年份:
    2022
  • 资助金额:
    $ 38.31万
  • 项目类别:
A phase 2 trial to evaluate safety and immunogenicity of a next-generation COVID-19 vaccine delivered by inhaled aerosol to humans
一项 2 期试验,旨在评估通过吸入气雾剂向人类输送的下一代 COVID-19 疫苗的安全性和免疫原性
  • 批准号:
    466312
  • 财政年份:
    2022
  • 资助金额:
    $ 38.31万
  • 项目类别:
    Operating Grants
Discovery of next-generation dengue NS4B inhibitors
下一代登革热 NS4B 抑制剂的发现
  • 批准号:
    10514156
  • 财政年份:
    2022
  • 资助金额:
    $ 38.31万
  • 项目类别:
Discovery of next-generation dengue NS4B inhibitors
下一代登革热 NS4B 抑制剂的发现
  • 批准号:
    10845865
  • 财政年份:
    2022
  • 资助金额:
    $ 38.31万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了